This October 11, 2017 email, from Catherine Robinson of Pfizer to Daniel Watson and John Meile of USTR, asks USTR to block a competitor from a tender to sell a drug. USTR provides one email and redacts details including the name of the product.
USTR also withheld 28 pages in full for three letters Pfizer submitted to the Federal Commission for the Protection against Sanitary Risk, a regulatory body of the Mexican government (Cofepris).